Cotización de Eiger BioPharmaceuticals, Inc. (EIGR) hoy en tiempo real
Análisis técnico y gráfico histórico de Eiger BioPharmaceuticals, Inc.
Análisis fundamental y estadísticas clave de Eiger BioPharmaceuticals, Inc.
Ficha de Eiger BioPharmaceuticals, Inc. (EIGR)
|
Ticker
|
EIGR
|
|
ISIN
|
US28249U2042
|
|
Sector
|
Atención sanitaria
|
|
Mercado
|
NASDAQ
|
Análisis financiero de Eiger BioPharmaceuticals, Inc.
Briefing
Valoración
Rentabilidad
Métricas por acción
Deuda
Liquidez
Resumen financiero e información corporativa de Eiger BioPharmaceuticals, Inc.
Ratios de valoración: PER, EV/EBITDA y métricas de Eiger BioPharmaceuticals, Inc.
Márgenes de rentabilidad y Cash Flow de Eiger BioPharmaceuticals, Inc.
BPA, Dividendos y Valor Contable: Métricas por acción de Eiger BioPharmaceuticals, Inc.
Solvencia y deuda: Análisis del balance de Eiger BioPharmaceuticals, Inc.
Ratios de liquidez y Test Ácido: Capacidad de pago de Eiger BioPharmaceuticals, Inc.
¿Qué es Eiger BioPharmaceuticals, Inc.?
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has compl...
¿En qué sector opera Eiger BioPharmaceuticals, Inc.?
Eiger BioPharmaceuticals, Inc. opera en el sector Healthcare, industria Biotechnology.